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ABSTRACT
Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia
(AML). To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor
is mandatory. We evaluated the effect of CD34 cell dose on survival in allogeneic bone marrow transplan-
tation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1). The 99
patients included in our analysis were classified into high CD34 cell dose group (CD34 cells> 2.5 106/kg)
and low CD34 cell dose group (CD34 cells < 2.5  106/kg). The high CD34 cell dose patients had better
overall survival (5-year overall survival rate, 75%  6% vs 52%  9%; P  .01) and leukemia-free survival
(5-year leukemia-free survival rate, 70%  6% vs 44%  9%; P  .04). CD34 cell dose was the only
independent prognostic factor in overall survival and leukemia-free survival. The high CD34 cell dose group had
a lower relapse incidence with a borderline statistical significance (5-year relapse rate, 27%  6% vs 50%  10%;
P  .09). There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute
graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between
the high and low CD34 cell dose groups. We confirmed that high CD34 cell dose favorably affects the
outcomes in allogeneic BMT for AML. The effort to attain a high CD34 cell dose should be pursued during
bone marrow harvest in allogeneic BMT for AML in CR1.
© 2005 American Society for Blood and Marrow Transplantation
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Allogeneic stem cell transplantation (ASCT) has
mproved the treatment outcome of acute myeloge-
ous leukemia (AML) in ﬁrst complete remission
CR1) with evidence of a beneﬁcial graft-versus-leu- t
22emia effect [1]. To improve the outcome after ASCT
or AML in CR1, efforts have been made to ﬁnd the
rognostic factors. The following prognostic factors
ave been found to have some possibility of predicting
urvival: age, sex, prior hepatitis, duration of symp-
oms at the time of presentation [2], acute graft-ver-
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Bus-host disease (GVHD), interstitial pneumonia, pre-
enting white blood cell (WBC) count [3], number of
nduction therapies needed to achieve CR, shorter
ime to attain CR [4], earlier time from diagnosis to
SCT [5], and cytogenetics [6,7]. These potentially
igniﬁcant prognostic factors cannot be modiﬁed, and
odiﬁable factors such as pretransplantation consoli-
ation therapy [8], preparatory regimen [9], GVHD
rophylaxis [10], and ASCT cell source [11-13] have
ot shown consistent and signiﬁcant differences in
verall outcome.
Infused cell dose, one of the modiﬁable factors,
as raised interest as a potential prognostic factor in
SCT for AML in CR1. The clinical relevance of
otal nucleated cell (TNC) number during ASCT was
dentiﬁed earlier in aplastic anemia [14]. TNC num-
er has been shown to predict survival of patients with
ematologic malignancies [15-20].
CD34 has been used as a surrogate marker of
ematopoietic stem cells. Several studies have inves-
igated the prognostic role of CD34 cell dose during
SCT in AML. Some studies have explored CD34
n speciﬁc settings, such as T-cell–depleted transplan-
ation [21,22] and human leukocyte antigen (HLA)
aplo-identical–related donor transplantation [23].
ther studies included heterogeneous patients in
erms of disease (eg, AML, acute lymphocytic leuke-
ia [ALL], chronic myelocytic leukemia [CML]) and
he risk of disease (ie, standard vs high) [24-26].
In the present study, we analyzed 99 patients with
ML in CR1 who underwent allogeneic BMT from
LA-identical sibling donors, to study the association
etween CD34 cell dose and clinical outcome.
ATERIALS AND METHODS
ata Collection and Patient Selection
Our study group included all patients fulﬁlling the
ollowing criteria in 3 institutions: (1) AML in CR1,
2) unmanipulated BMT, (3) HLA-identical sibling
onor, (4) transplantation between March 1992 and
anuary 2003, and (5) ﬂow cytometry analysis of
D34 cells.
efinition of Endpoints
Hematopoietic recovery. Neutrophil and platelet re-
overies were analyzed separately and deﬁned by an
bsolute neutrophil count (ANC)  .5  109/L for 3
onsecutive days and a platelet count  50  109/L
or 7 consecutive days with no platelet support, re-
pectively. The median time to recovery was calcu-
ated using the product-limit method.
Survival. Overall survival (OS) was deﬁned as the
ime interval from transplantation to death of any
ause. Leukemia-free survival (LFS) was deﬁned as the
ime interval from transplantation to the ﬁrst event p
B&MTeither relapse or death in CR). Transplant-related
ortality (TRM) was deﬁned as death in continuous
R, and relapsed patients were censored at the time of
elapse.
GVHD. Acute GVHD (aGVHD) was diagnosed
nd graded at each transplantation center according to
he Seattle criteria [27]. Only patients with grade II
nd higher were considered to have signiﬁcant
GVHD. Chronic GVHD (cGVHD) was deﬁned ac-
ording to standard criteria (limited and extensive)
28]. Patients surviving without relapse for 100 days
fter transplantation with sustained donor engraft-
ent were considered assessable for cGVHD.
D34 Cell Enumeration
Flow cytometry was used to determine CD34
ell count. Leukocytes were prepared from fresh bone
arrow using ammonium chloride lysis. The leuko-
ytes were incubated with pretitered antibody, washed
wice, and acquired using FACSort (Becton Dickin-
on, Franklin Lakes, NJ) or FACSCalibur (Becton
ickinson) with CELLQUEST software.
tatistical Analysis
All analyses were performed using the SPSS sta-
istical analysis program (SPSS, Chicago, IL). Quan-
itative variables were reported as median and range.
he following patient and graft characteristics were
nalyzed for their potential prognostic value on out-
ome: center, patient and donor characteristics (age,
ex, and sex matching), disease factors (WBC count at
iagnosis, French-American-British [FAB] classiﬁca-
ion, interval from diagnosis to CR1, interval from
R1 to transplantation, cytogenetic group [29]), and
ransplant-related factors (CD34 cell dose infused
er kilogram of recipient body weight, year of trans-
lantation, nature of the conditioning regimen includ-
ng total body irradiation [TBI] or not, GVHD pro-
hylaxis). For these prognostic analyses, continuous
ariables were categorized according to the median
alue, except for CD34 cell count. We analyzed data
ith various discriminating CD34 cell levels (.5, 1.0,
.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0). All CD34
ell dose levels showed superior OS and LFS in the
igher cell dose group than in the lower cell dose
roup with various degrees of statistical signiﬁcance,
ometimes reaching statistical signiﬁcance and some-
imes not. We also analyzed data using the median as
he discriminating point and obtained the same results
eaching statistical signiﬁcance. When quartiles were
sed, the higher CD34 cell dose group demon-
trated a trend toward superior OS and LFS (4th 
rd  2nd  1st quartiles). We concluded that 2.5 
06/kg is the most discriminating point after the re-
etitive analyses with variable cell dose discriminating
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1oints, although we cannot know the accurate, bio-
ogically relevant number.
To compare the distribution between the sub-
roups of patients, the 2 test was used for categorical
ariables and the nonparametric Mann-Whitney U
est was used for continuous variables. The probabil-
ties of OS, LFS, and TRM were estimated by the
roduct-limit method. The signiﬁcance of differences
etween curves was estimated using the log-rank test.
ll variables associated with outcome with a P value .1
n univariate analyses and all characteristics signiﬁ-
antly statistically different (P  .05) between sub-
roups of patients were included in a multivariate
nalysis. All multivariate analyses were adjusted on
enter.
ESULTS
atient Characteristics
We collected patients satisfying the previously de-
ned eligible criteria from 3 transplantation centers. A
able 1. Patient Characteristics
Characteristics Low (n 
enter
Center 1 8 (22%
Center 2 16 (43%
Center 3 13 (35%
ge (years)
Median (range) 34 (15-
ex
Female 15 (40%
ex matching
Female to male 7 (19%
Others 30 (81%
ge of donor (years)
Median (range) 30 (14-
BC count at diagnosis (109 L)
Median (range) 13.5 (.9-3
AB classification
M1/M2/M4 32 (86%
M5/M6/M7 5 (14%
nterval from diagnosis to CRI (d)
Median (range) 31.5 (14-
nterval from CRI to BMT (d)
Median (range) 96 (8-4
ytogenetics
Favorable 6 (17%
Intermediate 18 (51%
Unfavorable 8 (23%
Unknown 3 (9%)
ear of BMT
1992-1998 22 (59%
1999-2003 15 (41%
onditioning
No TBI 17 (46%
TBI 20 (54%
VHD prophylaxis
CSA only 2 (5%)
CSA  MTX 35 (95%
SA, cyclosporine A; MTX, methotrexate.otal of 99 patients with AML in CR1 were treated T
24ith allogeneic BMT from sibling full-matched do-
ors during the study period. Data on CD34 cell
ount were available for all patients included in this
nalysis.
The range of CD34 cell count was .1 to 18.2 
06/kg (median, 3.1  106/kg). Table 1 gives the
haracteristics of patients receiving allogeneic BMT
ith low ( 2.5  106/kg) versus high ( 2.5 
06/kg) CD34 cell dose. Patients with high CD34
ell dose underwent allogeneic BMT more often dur-
ng the recent period (P  .01) and more frequently
eceived non-TBI conditioning regimens (P  .02).
ematologic Recovery
Times to recovery of both neutrophils and plate-
ets were similar with low and high CD34 cell doses.
ll patients in both groups achieved ANC  .5 
09/L; however, 2 patients (5%) from the low CD34
ell dose group and another 2 patients (3%) from the
igh CD34 cell dose group failed to achieve an
ntransfused platelet count  50  109/L (P  .63).
High (n  62) P Value
.11
9 (15%)
40 (64%)
13 (21%)
.42
34.5 (16-48)
.09
36 (58%)
.66
14 (23%)
48 (77%)
.91
33.5 (13-55)
.81
11.4 (.6-141.6)
.29
58 (93%)
4 (7%)
.26
38 (14-105)
.96
90 (20-365)
1.00
10 (16%)
31 (51%)
15 (25%)
5 (8%)
.01
21 (34%)
41 (66%)
.02
43 (69%)
19 (31%)
.12
11 (18%)
51 (82%)37)
)
)
)
47)
)
)
)
51)
44.6)
)
)
105)
54)
)
)
)
)
)
)
)
)he median time to achieve ANC  .5  109/L was
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B5 days (range, 10-24) for the low CD34 cell dose
roup and 14 days (range, 10-21) for the high CD34
ell dose group (P  .16). The median time to achieve
n untransfused platelet count  50  109/L was 30
ays (range, 12-169) for the low CD34 cell dose
roup and 27 days (range, 15-151) for the high
D34 cell dose group (P  .27).
verall Survival
A total of 32 patients died of various causes. The
stimated OS at 5 years for the low CD34 cell dose
nd high CD34 cell dose groups was 52% 9% and
5%  6%, respectively (P  .01) (Figure 1). Female
ex of the recipient favorably inﬂuenced OS (P  .05)
nd unfavorable cytogenetics unfavorably inﬂuenced
S with a borderline statistical signiﬁcance (P  .09)
n univariate analysis. In multivariate analysis, CD34
ell dose was the only independent prognostic factor
n OS (Table 2).
Figure 1. Overall survival according to CD34 cell dose.
able 2. Results of Multivariate Analysis for OS and LFS
Outcomes and Variables HR (95% CI) P Value
S
CD34 > 2.5  106/kg .4 (.2-.9) .03
Center - .82
Sex - .12
Cytogenetics - .08
Year of BMT - .92
TBI - .92
FS
CD34 > 2.5  106/kg .5 (.3-1.0) .05
Center - .80
Sex - .25
Year of BMT - .40
TBI - .35nI, conﬁdence interval; HR, hazard ratio.
B&MTeukemia-Free Survival
A total of 30 patients relapsed, and 7 patients died
f nonleukemic causes. The estimated LFS at 5 years
or the low CD34 cell dose and high CD34 cell
ose groups was 44%  9% and 70%  6%, respec-
ively (P  .04) (Figure 2). Female sex of the recipient
P  .10) was associated with a favorable LFS with a
orderline statistical signiﬁcance in univariate analysis
P  .10). In multivariate analysis, CD34 cell dose
as the only independent prognostic factor in LFS
P  .05) (Table 2).
reatment-Related Mortality
A total of 7 patients died of nonleukemic causes. In
he low CD34 cell dose group, the causes of TRM
ere interstitial pneumonia in 2 patients (at 2.7 and
.9 months), veno-occlusive disease (VOD) in 1 pa-
ient (at 1.5 months), and hepatic failure in 1 patient
at 11 months). In the high CD34 cell dose group,
he causes of TRM were interstitial pneumonia in 1
atient (at 1.7 months), gastrointestinal bleeding in 1
atient (at 1.5 months), and VOD in 1 patient (at 2
onths). There was no signiﬁcant difference in TRM
etween the low CD34 cell dose and high CD34
ell dose groups (P  .27) (Figure 3).
elapse
A total of 30 patients relapsed. The estimated
elapse rate (RR) at 5 years for the low CD34 cell
ose and high CD34 cell dose groups was 50% 
0% and 27% 6%, respectively (P .09) (Figure 4).
o other prognostic factors demonstrated statistically
igniﬁcant differences in RR in univariate analysis.
VHD
The low and high CD34 cell dose groups did
Figure 2. Leukemia-free survival according to CD34 cell dose.ot differ in terms of risk of grade II-IV aGVHD. The
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1ncidence of grade II-IV aGVHD for the 2 groups was
6% and 8%, respectively (P  .32). There was no
ifference in the incidence of extensive-stage cGVHD
etween the low CD34 cell dose group (15%) and
he high CD34 cell dose group (19%) (P  .63).
ISCUSSION
We conclude that high CD34 cell dose is an
ndependent prognostic factor for OS and LFS for
ML patients in CR1 undergoing allogeneic BMT.
e took 2.5 106/kg as a CD34 cell dose threshold
o differentiate the 2 CD34 cell dose groups. The
edian CD34 cell dose was 3.1  106/kg, but a
D34 cell dose of 2.5 106/kg, if taken as a thresh-
ld for grouping these patients, produced a better
elineation of outcome variables.
A previous study [20] reported the relevance of
otal nucleated cell (TNC) dose in the same setting,
hat is, AML, CR1 allogeneic BMT from an HLA
ull-matched sibling. That study showed that high
NC dose ( 2.6  108/kg) was correlated with
etter LFS and that better LFS resulted from a lower
RM and lower relapse incidence in the high TNC
ose group. The authors reported 5-year LFSs of 46%
nd 68% in the low and high TNC dose groups,
espectively. Similarly, our results showed 5-year
FSs of 44% and 70% in the low and high CD34
ell dose groups, respectively (P  .04).
The classical concept of cell dose in allogeneic
MT has been limited to engraftment and rapidity of
ell recovery. A study of aplastic anemia demonstrated
hat high TNC dose reduced the incidence of graft
ejection [14]. A study of AML also focused on early
ortality [15]. Other studies of hematologic malig-
igure 3. Transplant-related mortality according to CD34 cell
ose. BMT indicates bone marrow transplantation.ancies with or without nonmalignancies showed that i
26igher bone marrow TNC dose was correlated with
ecreased deep fungal infection [17], decreased severe
GVHD and aGVHD-related mortality [16,18,19],
nd less nonleukemic death and better LFS [19]. The
forementioned studies focused on reduced nonleuke-
ic mortality from rapid cell recovery and decreased
isk of severe infection with higher bone marrow
NC dose. In addition to nonleukemic mortality, the
uropean Bone Marrow Transplantation study group
eported that a decreased relapse incidence in AML
as associated with higher bone marrow TNC dose
20].
Our trial is the ﬁrst report of the relevance of
D34 cell dose in allogeneic BMT in a homoge-
eous AML patient group. Higher CD34 cell dose
eﬁnitely improved LFS (P  .04) and OS (P  .01).
hether improved outcome in this study resulted
rom either decreased relapse mortality or decreased
onrelapse mortality cannot be answered. Although
ecreased relapse incidence and TRM were observed
n the high CD34 cell dose group, the differences
id not reach statistical signiﬁcance (P  .09 and P 
20, respectively). The failure to reach statistical sig-
iﬁcance was possibly due to the relatively small sam-
le size.
The relevance of CD34 cell dose in allogeneic
MT was evaluated in heterogeneous patient groups
25,26]. These trials demonstrated that higher
D34 cell dose was associated with lower TRM and
etter OS. A study of CD34 cell dose in BMT for
arious risk groups of hematologic malignancies
howed that improved LFS was due to decreased
RM but not decreased relapse rate, in contrast to
eripheral stem cell transplantation [26]. Other stud-
es reported that higher CD34 cell dose in periph-
ral stem cell transplantation showed a detrimental
igure 4. Relapse incidence according to CD34 cell dose. BMT
ndicates bone marrow transplantation.
e
a
l
i
i
s
C
r
f
d
t
b
t
m
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
CD34 Cell Dose in Allogeneic BMT for AML in CR1
Bffect by increasing TRM, especially higher cGVHD-
ssociated mortality [30,31]. The mechanism under-
ying the different effects of CD34 cell dose accord-
ng to stem cell source should be the subject of future
nvestigation.
We conﬁrmed that higher CD34 cell dose infu-
ion in BMT frommatched sibling donors for AML in
R1 improved OS and LFS. Our results suggest that
eal-time determination of CD34 count and an ef-
ort to collect higher CD34 cell doses should be
one in this setting. But it remains uncertain whether
he beneﬁcial effect of higher CD34 cell dose could
e extended to the unrelated donor scenario, because
he accurate mechanism of this effect was not deter-
ined.
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